<DOC>
	<DOC>NCT01009957</DOC>
	<brief_summary>The study will evaluate whether the administration of everolimus (1.5 mg/day) can slow down the progression of CKD in ADPKD patients.</brief_summary>
	<brief_title>Everolimus on CKD Progression in ADPKD Patients</brief_title>
	<detailed_description>Considering the inhibitor activity of Everolimus on mTOR, our hypothesis is to evaluate its possible utility on the progression of CKD in ADPKD patients by reducing the rate of increase of renal cysts.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1. Subjects over 18 years of both genders 2. Clinical diagnosis of autosomal dominant polycystic kidney disease (ADPKD) 3. GFR, according to MDRD formula, between 30 and 90 ml/min/1.73 mq 4. Previous follow up of two years, with a creatinine evaluation at least once a year 5. GFR reduction of at least 2.5 ml/min/year (according to MDRD formula) 1. Pregnancy, lactating, males and females without adequate contraception 2. Leucopenia (&lt; 3,000 leucocytes/mm3) or thrombocytopenia (&lt; 100,000 platelets/mm3) 3. Dyslipidemia (cholesterol or triglycerides &gt; 260 mg/dl with treatment) 4. Urinary tract infection 5. Patients who cannot undergoing NMR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>ADPKD</keyword>
	<keyword>CKD</keyword>
	<keyword>Renal disease progression</keyword>
	<keyword>Everolimus</keyword>
</DOC>